JeniVision Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

JeniVision General Information

Description

Operator of a biopharmaceutical company intended to discover and develop therapies in ophthalmology. The company's proprietary non-invasive ocular delivery pathway (NIODP) provides drug delivery to the retina with high bioavailability, enabling patients to prevent from developing blinding wet AMD disease.

Contact Information

Website
www.jenivision.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 5151 California Avenue
  • Suite 100
  • Irvine, CA 92617
  • United States
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 5151 California Avenue
  • Suite 100
  • Irvine, CA 92617
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

JeniVision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 18-Feb-2025 Completed Out of Business
2. Early Stage VC (Series A) 21-Sep-2018 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view JeniVision’s complete valuation and funding history, request access »

JeniVision Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view JeniVision’s complete cap table history, request access »

JeniVision Patents

  • 59

    Total Documents Applications and Grants

  • Total Patents Families

  • 23

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

JeniVision Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022396538-A1 Delivery methods for treating brain and central nervous system diseases Inactive 24-Nov-2021
CA-3231729-A1 Delivery methods for treating brain and central nervous system diseases Pending 24-Nov-2021
EP-4380559-A1 Delivery methods for treating brain and central nervous system diseases Inactive 24-Nov-2021
US-20240350447-A1 Delivery methods for treating brain and central nervous system diseases Pending 24-Nov-2021
WO-2023097296-A1 Delivery methods for treating brain and central nervous system diseases Inactive 24-Nov-2021 A61K31/202
To view JeniVision’s complete patent history, request access »

Ready to get started?

Request a free trial

JeniVision FAQs

  • When was JeniVision founded?

    JeniVision was founded in 2014.

  • Where is JeniVision headquartered?

    JeniVision is headquartered in Irvine, CA.

  • What industry is JeniVision in?

    JeniVision’s primary industry is Drug Delivery.

  • Is JeniVision a private or public company?

    JeniVision is a Private company.

  • What is JeniVision’s current revenue?

    The current revenue for JeniVision is .

  • How much funding has JeniVision raised over time?

    JeniVision has raised $7M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process